Work

Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?

Year: 2021

Type: article

Abstract: the FDA approved aducanumab, the first new drug for Alzheimer's disease in almost 20 years-and notably, the first drug with a putative disease-modifying mechanism for the treatment of this devastating disorder, namely the removal of β-amyloid (or Aβ) plaques from the brain.

Source: EMBO Molecular Medicine

DOI: 10.15252/emmm.202114781

Authors: Giovanna Lalli, Jonathan M Schott, John Hardy, Bart De Strooper

Institutions: UK Dementia Research Institute, University College London, UCL Queen Square Institute of Neurology, Hong Kong University of Science and Technology, VIB-KU Leuven Center for Brain & Disease Research, KU Leuven

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology (medical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,000

Funders: Parkinson's UK, Rosetrees Trust, Medical Research Council

Awards: Using genetic variability in whole transcriptome expression in cells and tissues to understand the pathogenesis of Parkinson's and Alzheimer's disease, G3327757157, Risk and Modifying factors in Fronto Temporal Dementia, G7979393549, Using Next Generation Sequencing to Unravel the Pathogenesis of Sporadic Inclusion Body Myositis - The International IBM Consortium Genetic Study

OpenAlex ID: W3190969996

FWCI: 8.714

Cites: 14

Cited by: 64

Related to: 10